Medical Ventures Corp.

Medical Ventures Corp.

September 17, 2007 09:00 ET

Medical Ventures Corp.: Metricath Used in Live Case at Cardiovascular Conference

Doctors observe device in use during C3 teaching case

RICHMOND, BRITISH COLUMBIA--(Marketwire - Sept. 17, 2007) - MEDICAL VENTURES CORP. (TSX VENTURE:MEV) announces that its Metricath Libra® arterial and in-stent measurement system was used in a live clinical demonstration at a recent U.S. cardiovascular conference. The device was used during an interventional procedure of a patient's peripheral arteries at the Capital Cardiovascular Conference (C3) in Harrisburg, PA.

Dr. Rajesh Dave, the C3 conference director and chairman of endovascular medicine at Harrisburg's PinnacleHealth Heart and Vascular Institute, performed a live case to show course registrants a method to treat complex diffuse disease. The procedure treated the patient's anterior tibial artery and renal artery.

"Visually assessing vessel diameter with peripheral angiography is notoriously inaccurate," Dr. Dave said in a statement after the procedure was completed. "I chose to use the Metricath to measure the diameter of the anterior tibial and renal arteries. The device was easy to prep and performed extremely well. I see it as a great and easy-to-use tool we can add to our armamentarium, to efficiently measure diameters of peripheral arteries during interventions to improve acute and long-term outcomes."

Dr. Stuart Pink, interventional cardiologist at PinnacleHealth Heart and Vascular Institute and another live case operator at C3, added:

"In this case we found the Metricath Libra balloon was very trackable and was able to be easily placed in an angulated renal artery to allow for diameter measurement."

This marks the second time this month that the Metricath System was highlighted at an endovascular training event, where instructors discussed or demonstrated the benefits of arterial and in-stent measurement to a group of practicing interventionalists. Metricath was recently featured in a discussion and in a pilot study presented at the New Cardiovascular Horizons conference in New Orleans.

"We are really pleased that some key opinion leaders in the interventional community have begun sharing their experiences using Metricath as a helpful tool for vascular sizing," said Paul Geyer, president and CEO of Medical Ventures. "Studies show that sub-optimal stent expansion is a frequent occurrence. When a doctor sees a live demonstration of how Metricath can change the course of treatment in a given case, it starts to have a real impact as to the device's clinical benefit. Sessions like what took place at C3 allow a broad group of specialists to observe Metricath's utility and ease of use. This is especially true in the peripheral arteries, where angiographic estimates can be misleading and sizing with IVUS may not be a viable option, or may result in additional time and cost."

About Metricath

The Metricath System is a balloon-tipped catheter used during angioplasty procedures to treat heart and vascular disease. The catheter features a low-pressure balloon that can precisely measure within arteries and stents, helping doctors with optimal stent selection and to confirm optimal stent expansion. The Metricath Libra is cleared for use in the United States, Canada, and the European Union.

About C3

C3 is a live case demonstration course featuring world-renowned faculty and extensive coverage of the leading clinical issues facing today's endovascular specialists. It promotes high-level education in advanced coronary, peripheral and carotid interventions, as well as technical issues, to interventional cardiologists, interventional radiologists and vascular surgeons.

About Medical Ventures Corp.

Medical Ventures Corp. develops, manufactures and commercializes medical devices for the quickly growing vascular and surgical marketplace. MEV products help doctors treat a wide range of health concerns, including vascular disease and obesity. MEV products include the Metricath® vascular measurement system and PeriPatch™, a line of surgical tissue products. Medical Ventures is also a contract medical devices manufacturer. For more information, please visit

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates", "believes", "may", "continues", "estimates", "expects", and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information